TheraCryf PLC TCF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX 0.85
- Day Range
- GBX 0.80–0.80
- 52-Week Range
- GBX 0.60–3.40
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 363.24 Mil
- Volume/Avg
- 12,393 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.90
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
- Website
- https://www.evgen.com
Valuation
|
Metric
|
TCF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.37 |
Price/Sales | 5.90 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TCF
|
|---|---|
Quick Ratio | 4.11 |
Current Ratio | 4.19 |
Interest Coverage | — |
Quick Ratio
TCF
Profitability
|
Metric
|
TCF
|
|---|---|
Return on Assets (Normalized) | −66.61% |
Return on Equity (Normalized) | −91.31% |
Return on Invested Capital (Normalized) | −77.90% |
Return on Assets
TCF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Gzqsyyxkp | Nvsr | $628.7 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Nttdxfxn | Dvrdqj | $122.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ydwnbsw | Hjfmb | $114.0 Bil | |||
| Moderna Inc
MRNA
| Gjnmytjgf | Czb | $45.3 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ycpddvm | Ssswxm | $31.8 Bil | |||
| argenx SE ADR
ARGX
| Mgssglv | Rlphx | $25.9 Bil | |||
| BioNTech SE ADR
BNTX
| Yqfvqhlhb | Kxbr | $19.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Bcynhnnk | Bwlrrv | $15.5 Bil | |||
| United Therapeutics Corp
UTHR
| Cqjrvnq | Ztlt | $14.0 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Ydmbhvpgq | Dyljh | $11.6 Bil |